The EGFR inhibitors, which are principally used in non-small cell lung cancers or breast cancers, may act on SARS-CoV-2 virus replication [22], whereas JAK2 inhibitors could act on SARS-CoV-2 cytokine storm because IL-6 and GM-CSF, which are stimulated in this infection, depend on JAK2 signaling [23]. Here, EGFR is linked to breast carcinoma.